NorthStar Medical Radioisotopes LLC

5249 Femrite Drive
Madison, WI 53718
Phone: 608.230.7160
Fax: 608.230.7180
Visit Website

RELATED CONTENT

New radiopharmaceutical Contract Development and Manufacturing Organization (CDMO/CMO) provides powerhouse combination of capabilities and expertise to advance patient care
News | Radiopharmaceuticals and Tracers

NorthStar Medical Radioisotopes Provides Updates on Corporate Progress ...

April 3, 2023 — NorthStar Medical Radioisotopes, LLC, a global innovator in the development, production and ...

Time April 03, 2023
Read more
Proprietary electron accelerator technology achieves “two beams on target” milestone, validating proof of concept for large-scale U.S. Mo-99 production without the use of uranium
News | Radiopharmaceuticals and Tracers

NorthStar Medical Radioisotopes Sets New Industry Precedent in ...

January 11, 2023 — NorthStar Medical Radioisotopes, LLC, a global innovator in the development, production and ...

Time January 11, 2023
Read more
News | Radiopharmaceuticals and Tracers

NorthStar Medical Radioisotopes Announces Supply Agreement with Aktis ...

August 26, 2022 — NorthStar Medical Radioisotopes, LLC, a global innovator in the development, production and ...

Time August 25, 2022
Read more
NorthStar will provide Clovis with its environmentally preferred, high purity non-carrier-added (n.c.a.) Ac-225
News | Radiopharmaceuticals and Tracers

NorthStar Medical Radioisotopes Announces Supply Agreement with Clovis ...

July 20, 2022 — -NorthStar Medical Radioisotopes, LLC, a global innovator in the development, production and ...

Time July 20, 2022
Read more
Curie Therapeutics will be provided with priority access to NorthStar’s high purity non-carrier added (n.c.a.) Ac-225, which will be used to advance its multimodal pipeline of precision radiopharmaceuticals to address broad unmet needs in treatment of patients with solid tumors
News | Radiopharmaceuticals and Tracers

NorthStar Medical Radioisotopes and Curie Therapeutics Announce ...

June 8, 2022 — NorthStar Medical Radioisotopes, LLC (‘NorthStar’), a global innovator in the development, production and ...

Time June 08, 2022
Read more
Convergent will use NorthStar’s Ac-225 to radiolabel its lead asset, CONV01-α, a prostate-specific membrane antigen (PSMA)-targeted monoclonal antibody, currently being investigated as a potential ground-breaking treatment for prostate cancer.
News | Prostate Cancer

NorthStar Medical Radioisotopes and Convergent Therapeutics Announce ...

March 11, 2022 — NorthStar Medical Radioisotopes, LLC, a global innovator in the development, production and ...

Time March 11, 2022
Read more
News | Molecular Imaging

NorthStar Medical Radioisotopes Expansion Event Unveils Advanced ...

October 29, 2021 — NorthStar Medical Radioisotopes, LLC, a global innovator in the development, production and ...

Time October 29, 2021
Read more
NorthStar Medical Radioisotopes, LLC, a global innovator in the development, production and commercialization of radiopharmaceuticals used for therapeutic applications and medical imaging, and POINT Biopharma Global Inc. (NASDAQ: PNT), a company accelerating the discovery, development, and global access to life changing radiopharmaceuticals, today announced the signing of a supply agreement for the therapeutic medical radioisotope actinium-225 (Ac-225).
News | Radiopharmaceuticals and Tracers

NorthStar Medical Radioisotopes and POINT Biopharma Announce Supply ...

September 10, 2021 — NorthStar Medical Radioisotopes, LLC, a global innovator in the development, production and ...

Time September 10, 2021
Read more
Wisconsin-based company will help secure U.S. supply of Mo-99 used in 40,000 medical procedures daily, promote nuclear nonproliferation
News | Nuclear Imaging

NNSA Awards $37 Million to Promote U.S. Production of Critical Medical ...

August 27, 2021 — The U.S. Department of Energy’s National Nuclear Security Administration (NNSA) issued two cooperative ...

Time August 27, 2021
Read more
Master Supply Agreement encompasses clinical development and commercial supply for Clarity’s Cu-67-based candidates to treat neuroblastoma, breast and prostate cancers, among others
News | Radiopharmaceuticals and Tracers

NorthStar Medical Radioisotopes Enters U.S. Supply Agreement for ...

June 22, 2021 — NorthStar Medical Radioisotopes, LLC, a global innovator in the development, production and ...

Time June 22, 2021
Read more
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now